Alexion sees FY13 non-GAAP EPS $2.82-$2.92, consensus $2.81 Sees FY13 $1.49B-$1.51B, consensus $1.49B. R&D expenses are expected to be in the range of $285M-$295M, and SG&A expenses in the range of $425M-$435M. The non-GAAP effective tax rate, reported on a cash tax liability basis, is expected to be in the range of 7%-9%.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.